Paxlovid is a medicine used to treat COVID-19 in adults who are more likely to get very sick. It comes as pills taken for a few days, starting soon after symptoms begin. One part stops the virus from copying itself, and the other part helps the first part stay in the body longer.
Every report comes from a Lived member, sent anonymously.
Have you tried Paxlovid (Nirmatrelvir / Ritonavir) for COVID-19?
Paxlovid is a prescription antiviral treatment for COVID-19 taken as pills at home. Each pack combines two medicines: nirmatrelvir, which acts directly against the virus that causes COVID-19, and ritonavir, a medicine first developed for HIV that is used here in a low dose to keep nirmatrelvir working. In the US it is approved to treat mild to moderate COVID-19 in adults who are at high risk of the illness becoming severe enough to need hospital care or to cause death. Higher risk usually comes from older age or a long-term condition such as diabetes, heart disease, high blood pressure, chronic lung or kidney disease, overweight or obesity, cancer, or a weakened immune system from illness or treatment. It is meant for the early days of the illness, started within five days of the first symptoms. Paxlovid is not approved to prevent COVID-19, either before or after an exposure, and it is not meant for people with no risk factors for severe illness. A dose for children has not been established.
To multiply, the COVID-19 virus first builds long protein chains that must be cut into working parts by a viral enzyme called the main protease. Nirmatrelvir blocks this enzyme, so the virus cannot finish making new copies of itself. Slowing that copying gives the immune system a better chance to bring the infection under control, which is why the treatment is started early, while the virus is still multiplying. On its own, nirmatrelvir is broken down quickly by a group of liver enzymes known as CYP3A. Ritonavir slows those enzymes, so nirmatrelvir stays in the blood at levels high enough to work. Ritonavir does not act against the COVID-19 virus itself. The same enzyme-slowing effect is the reason Paxlovid interacts with so many other medicines, because a large number of common drugs are cleared by CYP3A too.
Paxlovid comes as a blister pack holding both kinds of tablets. The usual dose is two nirmatrelvir tablets and one ritonavir tablet, all three taken together, twice a day (morning and bedtime) for five days. It can be taken with or without food, at about the same times each day. The tablets should be swallowed whole, not chewed, broken or crushed. Both medicines are needed: nirmatrelvir without ritonavir does not reach effective levels. Kidney function changes the dose. It is estimated from a blood test called eGFR (estimated glomerular filtration rate), where lower numbers mean weaker kidney filtering. An eGFR from 30 to below 60 calls for a lower dose, one nirmatrelvir tablet with one ritonavir tablet twice a day. Below 30, including people on dialysis, the schedule is once a day, taken after dialysis on dialysis days. These come in different packs, so check that the pack matches what the prescriber described. Paxlovid is not recommended for people with severe liver disease. Finish all five days even if you feel better. If a dose is less than eight hours late, take it as soon as you remember. If more than eight hours have passed, skip it and take the next dose at the usual time. Never double a dose to catch up.
The most common side effect is a change in taste, reported by about 5 in 100 people taking Paxlovid in its main trial compared with fewer than 1 in 100 on placebo. Diarrhea was the other common one (about 3 in 100 versus 2 in 100). Nausea, vomiting, stomach pain, headache, feeling generally unwell and raised blood pressure have also been reported in wider use. In the trial, fewer people stopped Paxlovid because of side effects than stopped the placebo. Allergic reactions are uncommon but can be serious, and they can happen even after the first dose. Stop Paxlovid and contact the prescriber at the first sign of a rash, hives or other skin reaction. Swelling of the lips, tongue, face or throat, hoarseness, or trouble breathing or swallowing can signal anaphylaxis, a severe allergic reaction, and needs emergency care right away (call 911). Serious skin reactions, including Stevens-Johnson syndrome, have also been reported rarely. Ritonavir can occasionally inflame the liver. Yellowing of the skin or eyes is worth reporting to the prescriber promptly, and anyone with existing liver disease should make sure the prescriber knows before starting.
Paxlovid's most important warning concerns other medicines, and the FDA label carries a boxed warning, its most serious kind, about it. Because ritonavir slows CYP3A, it can sharply raise the levels of other drugs the body clears the same way, sometimes to severe, life-threatening or fatal levels. Before prescribing, the prescriber or pharmacist should review everything you take, including over-the-counter medicines and supplements. Many interactions can be managed by pausing a medicine during the five days, lowering its dose or monitoring more closely. Some medicines cannot be combined with Paxlovid at all. The combinations that most often need a plan include tacrolimus and cyclosporine (immune-suppressing drugs used after transplants), which caused the most reported serious interaction harms, and calcium channel blockers for blood pressure such as amlodipine. Others are the cholesterol drugs simvastatin and lovastatin, which are paused around treatment, and atorvastatin, which may be paused during it; blood thinners such as rivaroxaban (Xarelto), apixaban (Eliquis) and warfarin, where bleeding risk can rise; opioid pain medicines such as oxycodone and fentanyl, where higher levels can dangerously slow breathing; and some heart rhythm, sedative, migraine and psychiatric medicines. A few medicines work the other way and can make Paxlovid ineffective, including St. John's wort (an herbal supplement), rifampin (an antibiotic used for tuberculosis) and the seizure medicines carbamazepine and phenytoin. They rule Paxlovid out even when recently stopped. Paxlovid can make birth control pills containing estrogen less reliable, so an added non-hormonal method such as condoms is advised during treatment and until one menstrual cycle after finishing. In people with HIV that is untreated or undiagnosed, the ritonavir may lead to HIV drug resistance. Information about nirmatrelvir in pregnancy is limited, though ritonavir has not been linked to birth defects and untreated COVID-19 itself carries risks in pregnancy. Small amounts of both medicines pass into breast milk.
Paxlovid is a short course, and its main benefit is one people do not directly feel: a lower chance of becoming seriously ill. In the main trial, run in 2021 in high-risk adults who had never been vaccinated or infected, about 1 in 100 people who took Paxlovid were hospitalized or died within four weeks, compared with between 6 and 7 in 100 on placebo. Most people now have some immunity from vaccines or past infection, and a later trial in vaccinated people with risk factors and in lower-risk people did not show faster symptom relief (a median of 12 days to feel well versus 13 on placebo). The reduction in hospital stays in that trial was small and not statistically certain. For people at lower risk, Paxlovid may not noticeably shorten the illness. Some people feel better and then have symptoms return or test positive again shortly after finishing, often called COVID rebound. Rebound also happens without treatment, but studies have found it more often after Paxlovid. Tell the care team if symptoms return or worsen. Any medicine paused for Paxlovid should be restarted only when the prescriber says, since some need a gap of several days after the last dose.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Paxlovid (Nirmatrelvir / Ritonavir), what you've noticed, or ask the community a question.